Bryan Kobel

$TCBP Announces Grant of European #Patent for Targeting of Microbial, #Oncological, and Viral Indications using Modified Gamma Delta T Cells finance.yahoo.com/news/tcbp-anno…

@123Kiki @Unluckiest2083 the stock closed below $1 for 30 days as part a short and distort campaign that was placed against the company last fall. This delisting is a result of that.

@Unluckiest2083 @CEO_TCBioPharm My understanding was that a stock had fall below a dollar to be de-listed where did I go wrong?

@CEO_TCBioPharm any reason why you decided to delist $TCBP when only a few months ago you said this

@Unluckiest2083 This attack on company stock price was a direct result of fraud. Subsequently, we put in front of Nasdaq panel a very strong case showing our commitment and track record of compliance. They moved to delist us.

@Unluckiest2083 $TCBP was part of a "short and distort" campaign. We made a concerted effort but the stock never recovered and "closed", not "traded" below $1 for 30 straight days. We chose not to split the stock because we had several key announcements and hoped to avoid hurting investors.

@seoljaeryong @TCBioPharm If you have a legitimate question, I encourage you to reach out to our company directly. ir@tcbiopharm.com

@CEO_TCBioPharm @TCBioPharm If it's for shareholders, please give me the ingredients to raise the stock price right away

$TCBP Announces Non-Binding Letter of Intent to #Acquire #Commercial #Stage Ophthalmic Pharmaceutical Company finance.yahoo.com/news/tcbp-anno…

$TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead The company is expected to reduce core operational burn by 55% when compared to 2024 ir.tcbiopharm.com/news/press-rel…

@seoljaeryong @TCBioPharm Management's goal is to enhance shareholder value

@CEO_TCBioPharm @TCBioPharm Don't Kill Retail Shareholders With Stock Dilution Retail Investors Are Down Right Now

@benchling @BBCNews @sajithw Great to hear this type of #optimism in the #biotech space

🔮 2025 is going to be a big year for #biotech. On @BBCNews, our CEO @sajithw explains why the industry is on the cusp of a faster, more automated, and #AI-driven future. 📺 Watch the full interview: benchling.com/news/opportuni…

@seoljaeryong @TCBioPharm Financing terms will be disclosed when appropriate

@CEO_TCBioPharm @TCBioPharm What money are you going to use to buy it? I'm sure you'll have RS again

@TCBioPharm Looking forward to seeing everyone here: sachsforum.com/18elsf-about.h…

$TCBP @CEO_TCBioPharm to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum finance.yahoo.com/news/tcbp-ceo-…

@Jzekester35 I certainly am not halting any "market runs".

$tcbp @CEO_TCBioPharm When you going to let the market run?

@professorDman1 We're actively communicating updates to the market, speaking with investors and working diligently to progress clinical trials.

Why is your stock $2s Mr. @CEO_TCBioPharm MC so low right now .. my calculations say it should be minimum $8 to $10+ range .. what are you doing homie ? You selling the company ?

@hyjr2 @TCBioPharm The conference was well attended and we held individual meetings with perspective investors on-site. We are also speaking with relevant investors regularly.

@TCBioPharm @CEO_TCBioPharm Thanks for sharing, but the pictures suggest low attendance. Can you clarify how successful the presentation was in attracting investors? Transparency builds confidence.

LIVE LOOK - @CEO_TCBioPharm Presenting on $TCBP at the #Sequire Investor Summit

@Jzekester35 @TCBioPharm While we can't comment on stock activity, we can continue to work on the development of much-needed, novel treatments.

@TCBioPharm @CEO_TCBioPharm Will this be the start of an upright trend in the stock market?

$TCBP Announces #H5N1 Proof of Concept Studies Intention finance.yahoo.com/news/tcbp-anno…

@2DMoon828741 We are and will continue to communicate any and all news to shareholders as it becomes available.

$TCBP shareholders, As stated in our 6k, the Company intends to appeal the notice to the Nasdaq Panel. This follows the same process we previously followed when receiving these notices from Nasdaq when we were in deficiency status.